Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585319 | 0.92 | MCHR1 (0.36) | MCHR1F10HDAC1HDAC2MMP2 | |
| SCHEMBL4583623 | 0.89 | F10 (0.38) | MCHR1F10HDAC1HDAC2 | |
| SCHEMBL3310190 | 0.87 | F10 (0.44) | MCHR1F10 | |
| SCHEMBL8487180 | 0.87 | F10 (0.44) | MCHR1F10 | |
| SCHEMBL13372818 | 0.87 | F10 (0.35) | F10HDAC1HDAC2MMP2BACE1 | |
| SCHEMBL13372902 | 0.86 | F10 (0.39) | MCHR1F10HDAC1HDAC2 | |
| SCHEMBL13372836 | 0.85 | F10 (0.33) | F10HDAC1HDAC2 | |
| SCHEMBL13372886 | 0.82 | F10 (0.46) | F10 | |
| SCHEMBL4583666 | 0.82 | CCNK (0.43) | MCHR1F10 | |
| SCHEMBL4583390 | 0.82 | CCNK (0.43) | MCHR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-1975165-A1 | Substituted pyrrolidinamides, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |